MedTrace Logo

Trial to Evaluate the Safety and Immunogenicity of a 20-Valent Pneumococcal Vaccine in Adults 65 Years of Age or Older With Prior Pneumococcal Vaccination

NCT03835975 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 875

Last updated 2021-02-21

Study results available
· View outcomes & findings →

Summary

This Phase 3 will describe the safety and immunogenicity of a 20-valent pneumococcal conjugate vaccine formulation in adults 65 years of age or older with prior pneumococcal vaccination

Conditions

  • Pneumococcal Disease

Interventions

BIOLOGICAL

13vPnC

Pneumococcal conjugate vaccine

BIOLOGICAL

PPSV23

Pneumococcal polysaccharide vaccine

BIOLOGICAL

20vPnC

Pneumococcal conjugate vaccine

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-02-12
Primary Completion
2020-02-12
Completion
2020-02-12
FDA Drug
Yes

Countries

  • United States
  • Sweden

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03835975 on ClinicalTrials.gov